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Isocitrate lyase is important for lipid utilisation by Mycobacterium tuberculosis but its ICL2
isoform is poorly understood. Here we report that binding of the lipid metabolites acetyl-CoA
or propionyl-CoA to ICL2 induces a striking structural rearrangement, substantially increasing
isocitrate lyase and methylisocitrate lyase activities. Thus, ICL2 plays a pivotal role regulating
carbon ﬂux between the tricarboxylic acid (TCA) cycle, glyoxylate shunt and methylcitrate
cycle at high lipid concentrations, a mechanism essential for bacterial growth and virulence.
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The ability of Mycobacterium tuberculosis (Mtb) to pre-ferentially utilise lipids as its carbon source is a metabolicfeature that enables chronic infection1–4. Isocitrate lyase
(ICL) isoforms 1 and 2 (Supplementary Fig. 1) are key enzymes in
this process, through their roles in the glyoxylate and methylci-
trate cycles (Supplementary Fig. 2)5,6. Both enzymes are essential
for in vivo growth and virulence7,8, but most studies have focused
on the roles and structure of ICL16,8,9, leaving our understanding
of ICL2 hampered by the lack of structural, functional and
mechanistic insight.
Herein, using X-ray crystallography, we report the ﬁrst struc-
tures of ICL2. Enzymatic assays and molecular dynamics calcu-
lations reveal that ICL2 is activated by the binding of acetyl-CoA
or propionyl-CoA. Our results provide strong evidence that ICL2
may act as a gate-keeping enzyme, allosterically regulating the
glyoxylate shunt and the methylcitrate cycle, an essential
mechanism during chronic infection when Mtb uses lipids as the
primary carbon source.
Results
Structure of ligand-free ICL2. We determined the crystal
structure of ligand-free ICL2 from Mtb CDC1551 at 1.8 Å reso-
lution (Fig. 1a). The 766-residue ICL2 monomer crystallised as a
tetramer, with four subunits forming an elongated structure
(length ~200 Å). Each subunit comprises two distinct domains,
with the N-terminal (residues 1–590) and the C-terminal (resi-
dues 603–766) domains connected by a ﬂexible linker (residues
591–602) (Supplementary Fig. 3). The N-terminal domain con-
tains the α/β-barrel core common to all ICLs and is packed
similarly to that in Mtb ICL19. It also possesses an active site loop
containing the conserved catalytic motif 213KKCGH217, as in
ICL1. However, the ICL2 N-terminal domain possesses an
additional helical substructure that is not present in Mtb ICL1
(helices α10–α16; residues 278–427) (Supplementary Fig. 3).
While such a structural insert is uncommon in bacterial ICLs, it is
often present in fungal homologues10,11.
The C-terminal domain of Mtb ICL2 is unique to this isoform,
with no sequence homology to known proteins. However,
structural searches12–14 revealed similarities to members of the
Gcn5-related N-acetyltransferase (GNAT) superfamily, despite
showing only 5–15% sequence identity (Supplementary Fig. 4).
The C-terminal domains from two monomers associate at each
end of the ICL2 structure (Fig. 1c), forming a barrel-like
structure. The association appears weak, as conﬁrmed by small-
angle X-ray scattering (SAXS), which gives an experimental
scattering proﬁle that can only be explained on the assumption
that multiple conformations are present in solution (Supplemen-
tary Fig. 5). We assume that crystal packing has selected one of
several accessible conformational states.
ICL2 is activated by acetyl-CoA and propionyl-CoA. The
structural resemblance of the Mtb ICL2 C-terminal domain to
members of the GNAT superfamily prompted us to investigate
the potential modulation of ICL2 activity by acetyl-CoA, which is
the main product of fatty acid β-oxidation. The activity of Mtb
ICL2 was measured by a nuclear magnetic resonance (NMR)-
based assay that directly monitors reaction turnover (Supple-
mentary Fig. 6a)15 and a ﬂuorescence-based continuous assay
that relies on the reaction between glyoxylate and phenylhy-
drazine (Supplementary Fig. 6b)16. Both assays gave comparable
results; in agreement with previous studies6, ICL2 showed poor
isocitrate lyase activity using DL-Isocitrate as a substrate (kcat/KM
755 ± 70M−1 s−1 at 27 °C) (Fig. 2a, Supplementary Fig. 7 and
Supplementary Table 1). However, in the presence of acetyl-CoA,
ICL2 displayed a remarkable 50-fold increase in catalytic efﬁ-
ciency (kcat/KM 37,200 ± 6000M−1 s−1 at 27 °C) (Fig. 2a, Sup-
plementary Fig. 7 and Supplementary Table 1). The KM value for
the cofactor acetyl-CoA is 2.9 ± 0.5 μM (Supplementary Fig. 8),
indicating it is a relatively strong binder to Mtb ICL2. The pre-
sence of the inactive L-isomer of isocitrate did not affect the
catalytic activity of Mtb ICL2 or its allosteric activation by acetyl-
CoA (Supplementary Fig. 10). This increase in catalytic activity
upon the addition of acetyl-CoA appeared to be speciﬁc to Mtb
ICL2, as addition of acetyl-CoA to Mtb ICL1 has no effect on the
catalytic activity (Supplementary Fig. 11).
We then tested the methylisocitrate lyase activity of Mtb ICL2;
no methylisocitrate lyase activity was detected with Mtb ICL2
alone (Fig. 2b, Supplementary Fig. 7 and Supplementary Table 1).
a b c
Fig. 1 Structure of ICL2. a Ligand-free ICL2 forms an elongated structure with C-terminal dimers at each end of the structure. b Striking structural
rearrangement of ICL2 upon binding to acetyl-CoA. In both a and b, each monomer is shown in different colours and the schematics outline the structural
features of the tetramer in each case. c The dimeric association of the C-terminal domains in the ligand-free (top) and acetyl-CoA-bound (bottom) ICL2.
Acetyl-CoA is shown as spheres in panels b and c. Both panels are shown with the same orientation of the wheat-coloured monomer
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However, Mtb ICL2 was found to catalyse the turnover of
methylisocitrate as a substrate in the presence of acetyl-CoA to an
extent similar to ICL1 (kcat/KM 1240 ± 175M−1 s−1 and 1330 ±
100 for ICL2 and ICL1, respectively) (Fig. 2b and Supplementary
Table 1). Propionyl-CoA, an intermediate of odd-chain fatty acid
oxidation and cholesterol metabolism, also leads to an increase in
the isocitrate lyase and methylisocitrate lyase activity of ICL2
(Supplementary Figs. 7, 8 and 9). Succinyl-CoA and CoA also
activate ICL2, albeit to a lesser extent (Supplementary Fig. 7).
Overall, our results imply that ICL2 occupies an unprecedented
role in the glyoxylate shunt and methylcitrate cycle of Mtb.
Acetyl-CoA triggers striking conformational changes in ICL2.
To understand these results, we determined the crystal structure
of Mtb ICL2 in the presence of acetyl-CoA at 2.36 Å resolution
(Fig. 1b). One molecule of acetyl-CoA binds to each of the
C-terminal domains in the tetramer, inducing striking con-
formational changes. Acetyl-CoA binding is mediated by exten-
sive hydrogen bond interactions, which are exclusively formed
with residues in the C-terminal domains (Supplementary Fig. 12).
In the acetyl-CoA-bound structure, the C-terminal domain from
one monomer moves an average of 77 Å towards the centre of
ICL2 and rotates ~176° to form a new dimer with the C-terminal
domain from the opposing monomer (Fig. 1c). The two
C-terminal dimers formed when acetyl-CoA binds seem to be
more stable as indicated by the buried interface area (1105 Å2)
compared with the area in the ligand-free form (975 Å2). These
distinctive conformational changes seen in the crystal structures
are conﬁrmed by the SAXS scattering proﬁles for ICL2 in the
presence of acetyl-CoA, which are markedly different from that of
ligand-free ICL2 (Supplementary Fig. 5).
Molecular dynamics (MD) simulations for both the ligand-free
and acetyl-CoA-bound ICL2 structures were conducted to
investigate the mechanism of the observed allosteric activation
of Mtb ICL2 upon acetyl-CoA binding. Both structures show
similar overall residue ﬂexibilities, with local changes in regions
associated with the reorganisation of the C-terminal domains
(Supplementary Fig. 13a). Upon binding of acetyl-CoA, the loop
consisting of residues 637–643 becomes more rigid due to the
formation of the new dimer interface between the C-terminal
domains. On the other hand, residues 382–388 become slightly
more ﬂexible, due to loss of interactions with the C-terminal
domains resulting from the conformational change. Comparing
the average structures of the C-terminal domains obtained from
MD simulations shows two regions with clear local conforma-
tional changes, including residues 635–640 and residues 730–739
(Supplementary Fig. 13b). Both regions are involved in the
formation of the new dimer interface between C-terminal
domains upon acetyl-CoA binding (Supplementary Fig. 13c).
Comparison of the C-terminal domain dimers by superimposi-
tion at one monomer shows a rotation between the monomers
upon acetyl-CoA binding (Supplementary Fig. 13d). Such
rotation requires a displacement of ~26 Å at the start of the
C-terminal domain (residue 603). However, due to the con-
straints from the length of the linker region, such large
movements would be prohibited in the ligand-free conformation,
making the repositioning of the C-terminal domains necessary in
order to form the new dimers upon acetyl-CoA binding.
Comparison of the average conformations of the N-terminal
domain (residues 1–590) obtained from MD simulations reveals
that the only region with clear conformational change upon
acetyl-CoA binding is in the active site loop (Supplementary
Fig. 13e). The changes in the conformations of the active site loop
were closely examined and compared with the conformations
observed in crystal structures of isocitrate-bound ICL1 from
Brucella melitensis (Bm ICL1, PDB 3P0X). Results suggest that in
acetyl-CoA-bound ICL2 the conformations of the active site loop
are more similar to that found in the crystal structure of
substrate-bound Bm ICL1 (Fig. 3a). The root-mean-square
deviation (RMSD) values between the active site loop in ICL1
(residues 183–187) and that in both ligand-free and acetyl-CoA-
bound ICL2 (residues 213–217) were calculated using the
trajectories obtained from MD simulations. The distribution of
the RMSD values in acetyl-CoA-bound ICL2 suggests a shift in
the active site loop conformation towards a more catalytically-
relevant conformation akin to that in substrate-bound Bm ICL1
(Fig. 3b). This is also conﬁrmed by replica exchange molecular
dynamic simulations (REMD), which was used to examine the
conformations sampled by the active site loop. Our results from
the REMD simulations also indicate that the active site
loop largely samples different conformations in the ligand-free
and acetyl-CoA-bound states (Supplementary Fig. 14). This
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Fig. 2 The catalytic activity of M. tuberculosis ICL2 is modulated by acetyl-
CoA. a The catalytic efﬁciency of ICL2 is increased ~50-fold upon addition
of acetyl-CoA with DL-isocitrate as a substrate. Reactions in the presence
of acetyl-CoA were conducted with 0.2 μM ICL2, 100 μM–1 mM DL-
isocitrate, 25 μM acetyl-CoA, 5 mM MgCl2 in 50mM Tris-D11 pH 7.5 in
90% H2O and 10% D2O. Reactions in the absence of acetyl-CoA were
conducted with 2 μM ICL2, 250 μM–2mM DL-isocitrate, 5 mM MgCl2 in
50mM Tris-D11 pH 7.5 in 90% H2O and 10% D2O. Reaction temperature
was 27 °C. The uncorrected concentrations of the substrate DL-isocitrate
were used. The error bars indicate standard deviations for three
independent experiments. KM and kcat values of ICL1 were obtained from
ref. 15. b While no detectable level of methylisocitrate turnover was
observed with ICL2 only, acetyl-CoA also increased the catalytic efﬁciency
of ICL2 when methylisocitrate was used as a substrate. The kcat/KM value in
the presence of acetyl-CoA is comparable to the value obtained for ICL1. 2-
Methylisocitrate was synthesised according to literature15. ICL2 reactions
were conducted with 1 μM ICL2, 250 μM–2mM 2-methylisocitrate, 25 μM
acetyl-CoA, 5 mM MgCl2 in 50mM Tris-D11 pH 7.5 in 90% H2O and 10%
D2O. ICL1 reactions were conducted with 2 μM ICL1, 250 μM–2mM 2-
methylisocitrate, 5 mM MgCl2 in 50mM Tris-D11 pH 7.5 in 90% H2O and
10% D2O. Reaction temperature was 27 °C. The error bars indicate
standard deviations for three independent experiments. Source data are
provided as a Source Data ﬁle
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conformational shift likely contributes to the underpinning
mechanism of the observed activation of ICL2 by acetyl-CoA.
The correlated residue motions during MD simulations reveal
two regions with high correlation, which interestingly corre-
sponds to the ICL2-unique helical substructure in the N-terminal
domain (α10–α16, residues 278–427), and the C-terminal acetyl-
CoA binding domain (Supplementary Fig. 15a). Residues
involved in correlated motions with either of the two regions
were identiﬁed (Supplementary Table 2), which show opposite
patterns between ligand-free and acetyl-CoA-bound ICL2. In the
ligand-free enzyme, N-terminal domain residues are mostly
affected by the motion of helices α10–α16 (Supplementary
Fig. 15b), whereas in acetyl-CoA-bound ICL2, residues from
the N-terminal domain mostly move in correlation with the C-
terminal domain. Two residues from the active site loop (residues
214 and 215) showed correlation with the C-terminal domain in
acetyl-CoA-bound ICL2, indicating the repositioning of the C-
terminal domains has an inﬂuence on the movement of the active
site loop (Supplementary Fig. 15c).
Discussion
The regulation of carbon ﬂux between the tricarboxylic acid
(TCA) cycle and glyoxylate shunt is critical for Mtb, especially
given its ability to utilise multiple carbon sources simultaneously1.
Recent reports have attempted to dissect the potential mechan-
isms that control carbon ﬂux between the two cycles17–20. None
of these studies, however, have addressed the potential regulatory
role(s) of ICL2, whose function in Mtb lipid metabolism remains
poorly understood. We have shown that activation of the iso-
citrate lyase activity of ICL2 occurs upon acetyl-CoA and
propionyl-CoA binding, thus uncovering the unique role this
isoform plays in the allosteric regulation of the glyoxylate shunt at
high lipid concentrations. It appears that ICL2 acts as a gate-
keeping enzyme to shift the carbon ﬂux between the TCA cycle
and the glyoxylate shunt, especially when lipids are utilised as the
main carbon source. In addition to its role in the glyoxylate cycle,
we have also unravelled the role of ICL2 in the methylcitrate
cycle. Although ICL2 does not appear to have any methylisoci-
trate lyase activity in the absence of allosteric activators, we have
shown that acetyl-CoA and propionyl-CoA switch on the
methylisocitrate lyase activity of ICL2. The allosteric activation of
ICL2 in response to increasing cellular propionyl-CoA may be a
mechanism to alleviate the toxicity of the methylcitrate cycle
intermediates during growth on odd-chain fatty acids or
cholesterol21,22. Overall, these observations provide a molecular-
level understanding of ICL2 function in Mtb metabolism. The
structural and mechanistic details reported herein provide the
basis for the development of inhibitors against both ICL isoforms
as potential antitubercular agents23.
Methods
Recombinant protein production. A synthetic gene encoding ICL2 of M. tuber-
culosis CDC1551 was obtained from Integrated DNA Technologies (Supplemen-
tary Table 3), and then subcloned into pYUB28b24 for protein production
(Supplementary Table 4). Recombinant ICL2 was expressed in Escherichia coli
BL21 (DE3) LOBSTR cells transformed with the pGro7 plasmid (Takara Bio Inc.)
expressing GroEL/GroES chaperones under the araB promoter. ICL2 was pro-
duced by leaky expression at 37 °C in Terriﬁc Broth media containing 50 μg/mL
each of hygromycin and chloramphenicol. L-Arabinose (ﬁnal concentration 0.1%)
was added to the culture media when the cell density reached an OD600 of between
0.4 and 0.6. This was followed by further incubation at 37 °C for 16 h. The His6-
tagged ICL2 was puriﬁed by immobilised metal afﬁnity chromatography (IMAC)
and size exclusion chromatography (Supplementary Methods). Puriﬁed ICL2 ali-
quots were ﬂash-frozen in 20 mM HEPES pH 7.5, 150 mM NaCl and 1 mM β-
mercaptoethanol and kept at −80 °C until use.
Structural search. The C-terminal domain of ICL2 (residues 595–764) was
compared against the structures in the Protein Data Bank (PDB) using the DALI
server (http://ekhidna2.biocenter.helsinki.ﬁ/dali/)12 and the 3D-BLAST Protein
Structural Search online server (http://3d-blast.life.nctu.edu.tw/)13,14.
Enzyme kinetics using NMR spectroscopy. Enzyme kinetics were measured
using an NMR-based method developed in our laboratory15. In brief, all NMR
experiments were conducted at a 1H frequency of 500MHz using a Bruker Avance
III HD spectrometer equipped with a BBFO probe. The instrument was operated
by TopSpin 3.1 software. Experiments were conducted at 300 K. The pulse tip-
angle calibration using the single-pulse nutation method (Bruker “pulsecal” rou-
tine) was undertaken for each sample. Water suppression was achieved using the
excitation sculpting method. Unless otherwise stated, the number of transients was
16, and the relaxation delay was 2 s. Reactions were initiated by the addition ofMtb
ICL2. The lag time between the addition of enzyme and the end of the ﬁrst
experiment was usually 4 min. All measurements were performed in triplicate. All
experiments were conducted in 50 mM Tris-D11 (pH 7.5) in 90% H2O and 10%
D2O (500 μL volume). Five millimolar MgCl2 is also added to the reaction mixture.
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Fig. 3 Active site loop conformations in ICL2. a Active site loop (residues 213–217) conformations sampled during MD simulation for ligand-free (red) and
acetyl-CoA-bound (blue) ICL2. The active site loop in crystal structure of ICL1 in complex with isocitrate (PDB 3P0X) is superimposed and displayed as
thick yellow ribbons. The rest of the enzyme structures are displayed in white for clarity. b Distributions of the RMSD values between the active site loop in
ICL1 (residues 183–187, PDB 3P0X) and those in ligand-free and acetyl-CoA-bound ICL2 (residues 213–217)
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The exact components and their concentrations for each experiment are described
in the respective ﬁgure and table legends. Initial rates were obtained by non-linear
curve ﬁtting using SigmaPlot 13.0 with the “Single, 2 Parameter equation under
Exponential Rise to Maximum” equation category (f= a(1− e−bx)), in which f
denotes the concentration of the product succinate and x denotes time.
Enzyme kinetics using phenylhydrazine-coupled UV/vis assay. Enzyme
kinetics were measured as described16,25. In brief, all experiments were conducted
using transparent Nuclon Delta Surface 96-well plates (Thermo Scientiﬁc) with a
Perkin Elmer EnSpire Multimode Reader operating at room temperature (~21 °C).
All experiments were conducted in 50 mM Tris (pH 7.5) in 100% H2O (100 μL
volume). Five millimolar MgCl2 and 10 mM phenylhydrazine are also added to the
reaction mixture. Reactions were initiated by the addition of Mtb ICL2 into the
assay mixtures. The enzymatic product glyoxylate reacted with phenylhydrazine to
form a phenylhydrazone adduct (ε324= 17,000 M−1 cm−1), which was measured
spectrophotometrically at 324 nm. The absorbance was converted to concentration
using a calibration curve that was constructed using known concentrations of
glyoxylate and phenylhydrazine in the same reaction buffer. Initial rates were
obtained by using linear regression line ﬁtting in regions where turnover of the
substrate was <10%. All measurements were performed in triplicate. The exact
components and their concentrations for each experiment are described in the
respective ﬁgure and table legends.
Protein crystallography. Ligand-free ICL2 crystals were obtained by sitting drop
vapour diffusion, using a protein solution comprising 8 mg/mL ICL2, 1 mM suc-
cinate and 1 mM MgCl2 with the Morpheus screen26. Cubic-shaped crystals
typically grew in ~15 days using a precipitant comprising 9% w/v PEG 4000, 18%
v/v glycerol, an amino acid mix (0.02 M each of L-glutamate, DL-alanine, glycine,
DL-lysine, DL-serine) and 0.1 M MES/imidazole pH 6.9. Diffraction data were
collected using the MX1 and MX2 beamlines at the Australian Synchrotron. All
datasets were indexed and processed using XDS27, and scaled with AIMLESS28
from the CCP4 programme suite29. Full data collection and processing statistics are
given in Supplementary Table 5.
The structure was solved by molecular replacement with Phaser30 using
isocitrate lyase of Aspergillus nidulans (PDB 1DQU)10 as a search model. This
resulted in a protein model that contained only the N-terminal domain. The initial
structure was improved to obtain the complete protein model containing both N-
and C-terminal domains by visual inspection and model building with cycles of
automatic (phenix.autobuild31) and manual (COOT32) model building. This
structure was reﬁned at 2.90 Å resolution using REFMAC533.
Additive screens around the most promising condition using the Morpheus
additive screen, resulted in a crystal that formed in the presence of 0.001M sodium
tungstate dihydrate. A new dataset was collected from this crystal and used to solve
the structure, using the afore-mentioned ligand-free ICL2 as a search model. The
ﬁnal structure was reﬁned to 1.8 Å resolution, with crystallographic Rvalue of
16.83% and Rfree of 20.25%. Water molecules were identiﬁed by their spherical
electron density and appropriate hydrogen bond geometry with the surrounding
structure. Despite the presence of succinate in the crystallisation drops, no clear
electron density could be observed for this molecule. Full reﬁnement statistics are
shown in Supplementary Table 6.
Co-crystals of an ICL2-acetyl-CoA complex were grown from a solution
containing 6 mg/mL ICL2, 1 mM acetyl-CoA and 1 mM MgCl2 (crystal form I).
The best diffracting crystals were obtained in a solution comprising 8% w/v PEG
4000, 16% v/v glycerol, amino acids mix (0.02 M each of L-glutamate, DL-alanine,
glycine, DL-lysine, DL-serine) and 0.1 M MES/imidazole pH 6.5. The structure was
solved by molecular replacement with MOLREP34 using the ligand-free
ICL2 structure as a search model. An initial partial model was obtained using just
the N-terminal domain of ligand-free ICL2, followed by using this partial solution
as a ﬁxed model to search for the C-terminal domain. Model building using phenix.
autobuild and COOT resulted in a complete model that was reﬁned at 2.67 Å
resolution, with crystallographic Rvalue of 21.87% and Rfree of 24.10%. The structure
showed unambiguous electron density for acetyl-coA in all four subunits, with no
clear electron density for succinate.
In an additional experiment, 3-nitropropionic acid (3-NP), an inhibitor of
ICL135, was also added to the co-crystallisation drops containing ICL2, acetyl-CoA
and MgCl2 (crystal form II). A crystal was obtained from a solution containing of
8% w/v PEG4K, 16% v/v glycerol, alcohols mix (0.02 M each of 1,6-hexanediol, 1-
butanol, (RS)-1,2-propanediol, 2-propanol, 1,4-butanediol, 1,3-propanediol) and
0.1 M MES/imidazole pH 6.9, which diffracted to 2.36 Å resolution, and was solved
using the form I structure as a search model. This structure, with crystallographic
Rvalue of 19.82% and Rfree of 23.24%, showed unambiguous electron density for
acetyl-coA in all four subunits, albeit with no clear electron density for either
succinate or 3-NP. Full reﬁnement statistics are shown in Supplementary Table 6.
Given the higher resolution of the form II structure, we have used this to discuss
the ICL2-acetyl-CoA complex throughout the paper. The PDB_redo program36
was used in the ﬁnal stages of reﬁnement for all structures. All structural ﬁgures in
the paper are produced using Pymol37.
Small-angle X-ray scattering (SAXS) analyses. ICL2 protein aliquots were
extensively dialysed against 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol (v/
v), and 1 mM TCEP (tris(2-carboxyethyl)phosphine). This buffer was used to make
the ligand solutions and to dilute protein samples. The 96-well plates containing
the samples were mounted on a temperature-controlled mount at 283 K for
autosampling and capillary ﬂow data acquisition, comprising consecutive 1-s X-ray
exposures. SAXS data were collected on the Australian Synchrotron SAXS/WAXS
beamline and processed using the scatterBrain software package38. FoXS and
MultiFoXS servers39 were used to compute SAXS proﬁles of ICL2 structures (X-ray
structure as well as calculated population-weighted ensembles) to the experimental
proﬁles (Supplementary Table 7).
Molecular dynamics simulations. MD simulations were conducted using NAMD
2.1240 and trajectories were visualised and analysed in VMD41. Crystal structures for
ligand-free and acetyl-CoA-bound ICL2 obtained in this study were used as starting
points for MD simulations. Initial force ﬁeld topology and parameters for acetyl-
CoA were obtained from CGenFF server (https://cgenff.paramchem.org)42–45, from
which parameters were assigned by analogy to existing parameters in the force ﬁeld.
A penalty score is given to each assigned parameter and those with large penalty
values were further reﬁned by Force Field Toolkit46. Additional explicit TIP3 water
molecules were added to solvate the protein molecules in a water box in VMD. Na+
and Cl− ions were added to balance the net charge of the water box. MD simulations
were conducted with CHARMM36 force ﬁeld47 at a constant temperature and
pressure (298 K, 1 atm). The cutoff distance for van der Waals interactions was set to
12 Å. In each simulation, the system was ﬁrst minimised for 5000 steps followed by
dynamics simulation conducted with 2 fs time steps. Three MD simulations were
conducted for each of ligand-free and acetyl-CoA-bound Mtb ICL2, initiated with
different random seeds. MD simulations were conducted for 274.5, 277 and 276.9 ns
for ligand-free enzyme, and 232.4, 236.6 and 236 ns for acetyl-CoA-bound Mtb
ICL2. The total simulation time for ligand-free enzyme is 828.4 ns and that for the
acetyl-CoA-bound enzyme is 705 ns. Considering there are four identical chains on
the symmetrical homotetramer of Mtb ICL2 in each simulation, effectively the total
amount of simulation time for each protein chain is 3.3 and 2.8 μs for ligand-free
and acetyl-CoA-bound Mtb ICL2, respectively. Trajectory frames were collected
every 100 ps. All MD simulations for ligand-free and acetyl-CoA-bound ICL2 fully
equilibrated after 100 ns of simulations, as indicated by the protein backbone RMSD
values (Supplementary Fig. 16). All analyses of MD trajectories were conducted
using the collected frames from the equilibrated time period. The correlations
between residue ﬂuctuations during MD simulations were analysed. The ﬂuctuations
were obtained by calculating the RMSD values for each residue inclusive of the side
chain atoms, between each frame of trajectory. The correlation coefﬁcients between
the residue ﬂuctuations were then computed as deﬁned by the Pearson product-
moment correlation coefﬁcient, in equation
Rij ¼
Cij
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Cii ´Cjj
p ; ð1Þ
where Cij is the covariance of xi and xj ; Cii and Cjj are the variance of xi and xj ,
respectively. The calculations and analyses of the correlation matrices were con-
ducted using python v3.6.5 and Jupyter Notebook v5.5.0.
Replica exchange molecular dynamics (REMD). REMD simulations (parallel
tempering) were conducted using NAMD 2.1240 and trajectories were visualised
and analysed in VMD41. The same starting points for ligand-free and acetyl-CoA-
bound ICL2 as in the MD simulations were used. Two sets of REMD were con-
ducted for each of the ligand-free and acetyl-CoA-bound ICL2 states. The ﬁrst set
is set up with 10 replicas exchanging between a lower-temperature range of
300–310 K, and the second set contains 10 replicas exchanging at a higher-
temperature range of 310–320 K. Attempts to exchange were made every
1000 steps of simulation. For the lower temperature REMD set, 51.2 ns of trajec-
tories per replica were collected for ligand-free system, and 48.8 ns per replica
collected for acetyl-CoA-bound system. For the high temperature REMD, 23.3 ns
per replica were collected for the ligand-free system and 22.7 ns per replica were
collected for the acetyl-CoA-bound system.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The coordinates and structure factors have been deposited in the Protein Data Bank
under accession codes 6EDW, 6EDZ and 6EE1. The source data underlying Fig. 2a and b
and Supplementary Figs. 6a, b, 7a, b, 8a, b, c, d, 9a, b, c, d, 10 and 11 are provided as a
Source Data ﬁle. Other data are available from the corresponding authors upon
reasonable request.
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